Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 90

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 90
---
450 Impairment of long-lived assets7,579 710 Total operating expenses82,810 112,420 Operating loss(43,897)(86,416)Interest income7,386 4,964 Foreign currency transaction, net— 38 Interest expense— (2,833)Change in fair value of warrant liabilities2,558 12,746 Change in fair value of contingent value right liability(36,900)(18,300)Change in fair value of forward contract liabilities(6,890)(149,600)Other income, net606 691 Loss before income taxes(77,137)(238,710)Income tax (expense) benefit(287)19,000 Net loss$(77,424)$(219,710)Other comprehensive loss:Foreign currency translation adjustment(21)(53)Unrealized gain on marketable securities— 11 Total comprehensive loss$(77,445)$(219,752)Net loss per share allocable to common stockholders:Basic$(4.48)$(49.76)Diluted$(4.49)$(49.76)Weighted-average common shares outstanding:Basic17,276,822 5,170,319 Diluted17,357,943 5,170,319 

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(Amounts in thousands, except share data)

 Options for     Accumulated Series ASeries ASeries ASeries B  Additional otherStockholders’ Preferred StockPreferred StockPreferred StockPreferred StockCommon stockpaid-inAccumulatedcomprehensiveequity SharesAmountAmountSharesAmountSharesAmountSharesAmountcapitaldeficitloss(deficit)Balance at December 31, 2022— $— $— — $— — $— 5,101,459 $1 $493,322 $(394,937)$(4,558)$93,828 Issuance of Series A Preferred Stock in private placement619.627 250 — — — — — — — — — — — Issuance of Series A Preferred Stock in connection with the Merger and settlement of related forward contract384,930